NewAmsterdam Pharma Co N.V Cash Flow Statement (2022-2025) | NAMS

Cash Flow Statement Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Operating Activities
Net Income -42.02M-38.29M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M
Share-based Compensation 7.62M5.56M5.39M6.01M7.92M8.29M8.00M9.41M15.21M15.18M15.01M
Gains from Sales and Divestitures 0.14M0.14M0.14M
Gains from Investment Securities 11.15M1.60M8.00M0.70M18.50M21.85M2.80M10.20M
Non-cash Items -0.01M5.23M279.67M195.40M145.76M297.98M8.86M9.66M10.10M
Cash from Operations -31.86M-29.30M-46.98M-33.07M-54.60M-53.98M-12.50M-37.48M-36.47M-37.67M-32.77M
Depreciation, Depletion & Amortization
Amortization of Deferred Charges -0.51M-0.47M-0.40M
Depreciation & Amortization (CF) 0.01M0.01M0.01M0.01M0.01M0.02M0.03M0.05M0.05M0.04M0.06M
Change in Working Capital
Change in Account Payables -2.92M4.33M-9.23M12.89M-8.31M-3.35M1.91M-3.20M2.25M-0.39M-2.27M
Change in Accured Expenses 7.00M-5.07M9.34M-5.80M-1.38M0.27M0.40M2.39M-4.95M1.44M0.64M
Investing Activities
Capital Expenditures 0.01M0.01M0.01M0.00M0.39M0.21M0.07M0.00M0.02M0.09M0.04M
Change in Acquisitions & Divestments 12.50M24.66M34.40M
Cash from Investing Activities -0.01M-0.01M-0.01M-0.00M-0.39M-0.21M-0.07M-62.18M2.85M-159.14M2.51M
Financing Activities
Other financing activities 0.52M1.59M
Change in Capital Stock
Shares Issued 2.39M6.23M0.00M8.76M4.66M0.34M7.92M3.42M5.62M
Misc.
Cash from Financing Activities 2.39M6.33M0.19M198.18M4.66M0.06M456.61M6.52M3.42M5.89M
Exchange Rate Effect 3.06M-1.63M-1.60M5.22M-2.50M-0.91M4.54M-7.94M3.77M8.83M0.22M
Change in Cash -29.48M-22.98M-46.80M-33.08M143.19M-49.53M-12.52M356.95M-27.09M-193.38M-24.37M
Beginning Cash Balance 467.73M470.79M439.68M415.11M373.53M337.95M480.24M435.25M414.79M775.51M757.25M562.78M
Free Cash Flow -31.87M-29.31M-46.98M-33.08M-54.99M-54.19M-12.58M-37.48M-36.48M-37.76M-32.81M
Net Cash Flow -29.48M-22.98M-46.80M-33.08M143.19M-49.53M-12.52M356.95M-27.09M-193.38M-24.37M